Smith & Nephew plc vs TJX Companies Inc — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while TJX Companies Inc trades at $138.76 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 13.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and TJX Companies Inc for 97 Days on average.
| SNN | TJX | |
|---|---|---|
Market Cap | $11.10B | $152.62B |
Volume | 1,051,703 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $37.17 | $168.41 |
52-Week Low | $26.42 | $122.84 |
Typical Hold Time | 121 Days | 97 Days |
Enterprise Value | $14.13B | $160.93B |
Dividend Yield | 2.95% | 1.38% |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
TJX trades at $138.75, down slightly by 0.04% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growing from $48.5B in 2022 to $56.4B in 2025, and net income margin expanding to 8.63%. Recent quarters have consistently beaten EPS expectations, and analysts project a consensus price target of $174.15, implying 28% upside. The stock is supported by robust cash flow from operations of $6.12B in 2025 and a healthy balance sheet with $5.34B in cash.
The outlook for TJX is positive, driven by earnings growth, market share gains in off-price retail, and Wall Street's strong buy consensus. Key risks include competitive pressures, consumer spending volatility, and elevated valuation multiples. The stock presents a compelling opportunity for growth-oriented investors, though near-term technical overbought conditions warrant caution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →